7th Annual TMC Antimicrobial Resistance and Stewardship Conference, Jan 17-19, 2024

MDRO Colonization in ICU Patients: Results from the DYNAMITE Cohort Study
Max Adelman, Houston Methodist

Applications of Caenorhabditis elegans for Identification of Treatments Against Antimicrobial-Resistant Bacteria
Lois Armendariz, Rice University

RSV Vaccines: Moving on to Recommendations
Robert Atmar, Baylor College of Medicine

Neonatal Stewardship
Michael Chang, Univ. of Texas Health Science Center Houston

Differences in Virulence Between the Two Clades of Multidrug-Resistant K. Pneumoniae ST258
Nathalie Chen, Univ. of Pittsburgh

Resistance and New Drugs for Mycobacterium Tuberculosis
Kelly Dooley, Vanderbilt Univ. Medical Center

In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy

Chetna Dureja, Texas A&M University Institute of BioSciences and Technology

Cefepime Heteroresistance is Prevalent Among Clinical Pseudomonas Aeruginosa Bloodstream Isolates and is Associated with Emergence of Resistance in Patients with Hematologic Malignancies
Stephanie Egge, Oregon Health & Science University

RSV Vaccines: The Road to Licensure
Hana El Sahly, Baylor College of Medicine

Antibiotic Resistance in Neisseria Gonorrhoeae
Yonatan Grad, Harvard School of Public Health, Boston, MA

DOOR Application Demonstration
Toshimitsu Hamasaki, George Washington University

Understanding the Molecular Epidemiology of Non-CTX-M ESBL-producing Enterobacterales in the MidAtlantic United States
Dariusz Hareza, Johns Hopkins Univ. School of Medicine

Evolving Epidemiology and Treatment of Invasive S. aureus Infections in Children
Sheldon Kaplan, Texas Children’s Hospital and Baylor College of Medicine

Intrinsic Antibiotic Resistance in Pseudomonas aeruginosa
Barbara Kazmierczak, Yale Univ.

Basis of Commensal Bacillota Resistance to a Novel PolC-type DNA Polymerase III Inhibitor, Ibezapolstat, and the “Narrower” Spectrum of Activity Towards Clostridioides difficile
Jacob McPherson, University of Houston

Novel Therapeutics Against Fungal Infections
Minh-Hong Nguyen, University of Pittsburgh, Pittsburgh, PA

Penicillin Resistance in Group A streptococci
Randy Olsen, Houston Methodist and Weill Cornell Medical College

Probiotics for Staphylococcus aureus: A Translational Approach
Michael Otto, NIH

Novel Dug Combinations to Address Antimicrobial Resistance
Warren Rose, Univ. of Wisconsin

Discovering Disparities in Clinical Characteristics and Outcomes Among Patients Treated in US Hospitals for Carbapenem-resistant Enterobacterales (Bloodstream) Infections
Felicia Ruffin, Duke University

Elucidating Molecular Mechanisms Underlying Successful Adaptation to Carbapenem Antimicrobials in High Risk Carbapenem Resistant Escherichia coli Lineages
William Shropshire, MD Anderson Cancer Center

Protecting Patients. Combating Antimicrobial Resistance. An Update from CDC
Arjun Srinivasan, Division of Healthcare Quality Promotion CDC

Functional Genomics of Difficult-to-Treat Enterococcal Isolates and Their Viral Adversaries
Madison E. Stellfox, Univ. of Pittsburgh

Emerging S. aureus Antimicrobial Resistance and Current Prescribing Practices for Patients Presenting to US Emergency Departments with a Purulent Skin and Soft Tissue Infection
Jesus Torres, University of California, Los Angeles, David Geffen School of Medicine